InteKrin Therapeutics, Inc.: Series C $20M

Posted in I - Series C, Q - 3Q08, R - WEST, X - Diabetes, X - Metabolism

InteKrin Therapeutics (Los Altos, CA) clinical-stage biopharmaceutical company focused on the development of products for diabetes, metabolism and obesity, closed a $20M Series C financing. Participants include Skyline Ventures, Sofinnova Ventures, OrbiMed Advisors, , Sears Capital Management and Vivo Ventures.

Syndexa Pharmaceuticals, Corp.: Series A $15M

Posted in I - Series B, Q - 2Q08, R - NORTH EAST, X - Metabolism

Syndexa Pharmaceuticals (Cambridge, MA) a metabolic drug discovery company, closed a $15M Series B financing. Participants include Yalcin Ayalsi.

Esperion Therapeutics, Inc.: Series A $22.8M

Posted in I - Series A, Q - 2Q08, R - MID WEST, X - Cardiology, X - Metabolism

Esperion Therapeutics (Ann Arbor, Michigan) developer of drug compounds to treat cardiovascular and metabolic disease, closed a $22.8M Series A financing. Participants include Aisling Capital, Alta Partners and Domain Associates.

Aldagen, Inc.: Series D $18.4M

Posted in I - Series D, Q - 2Q08, R - SOUTH EAST, X - Ischemia, X - Leukemia, X - Metabolism, X - Stem Cell

Aldagen (Durham, NC) development-stage biopharmaceutical company focused on regenerative cell therapies, closed a $18.M Series D financing. Participants include Intersouth Partners, Tullis-Dickerson, Harbert Venture Partners, and The Aurora Funds.

NGM Biopharmaceuticals, Inc.: Series A $25.5M

Posted in I - Series A, Q - 1Q08, R - WEST, X - Metabolism

NGM Biopharmaceuticals (Hillsborough, CA) an early-stage drug development company focused on metabolic diseases closed a $25.5M Series A financing. Participants include Column Group, Prospect Venture Partners and Rho Ventures.

Escoublac, Inc.: Series A $6.7M

Posted in I - Series A, Q - 1Q08, R - NORTH EAST, X - Diabetes, X - Metabolism, X - Obesity

Escoublac (Cambridge, MA) the first occupant in Biogen Idec new Innovation Incubator is developing treatments for metabolic diseases, type II diabetes and obesity, closed a $6.7M Series A financing. Participants include Biogen Idec.

Next Entries »

to top of page...